Why the study?
Does chlorthalidone reduce major cardiovascular outcome events or non-cancer-related deaths compared to hydrochlorothiazide in patients with hypertension?
Does chlorthalidone reduce major cardiovascular outcome events or non-cancer-related deaths compared to hydrochlorothiazide in patients with hypertension?
In a large pragmatic trial, chlorthalidone did not demonstrate superiority over hydrochlorothiazide for reducing major cardiovascular events or non-cancer-related deaths in patients with hypertension.
Chlorthalidone should not be routinely preferred over hydrochlorothiazide; confirms prior evidence against cardiovascular superiority in hypertension.
In this large pragmatic trial of thiazide diuretics at doses commonly used in clinical practice, patients who received chlorthalidone did not have a lower occurrence of major cardiovascular outcome events or non-cancer-related deaths than patients who received hydrochlorothiazide. (Funded by the Veterans Affairs Cooperative Studies Program; ClinicalTrials.gov number, NCT02185417.).
No takes yet. Share an insight, caveat, or question.
Ishani et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: